hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human
hVIVO plc (AIM & Euronext: HVO) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces
hVIVO saw record revenues for another year in 2022 as demand for its human challenge trials accelerated. And 2023 could see further gains.
EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
€3.2m contract for Venn Life Sciences with global pharmaceutical client
£5.2m RSV human challenge study contract with global biotechnology company in Asia Pacific and Notice of Trading Update
Cathal Friel’s latest venture, Poolbeg Pharma, a clinical-stage infectious disease firm spun out of Open Orphan, aims to tap into the almost €200 billion infectious disease market.
Phase I results for Imutex’s mosquito vaccine candidate published in leading peer-reviewed journal
Study cohort sizes increase as clients recognise the benefits of human challenge
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that